Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

NASDAQ:TPST

Overview | Financials
Company Name Tempest Therapeutics, Inc.
Symbol TPST
Currency USD
Price 2.03
Market Cap 45,101,119
Dividend Yield 0%
52-week-range 0.17 - 9.77
Industry Biotechnology
Sector Healthcare
CEO Mr. Stephen R. Brady J.D., LLM
Website https://www.tempesttx.com

An error occurred while fetching data.

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist

Related Stocks

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

7.23 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.448 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

8.18 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

42.48 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

0.633 USD

Financials

Numbers are in millions USD

Numbers are in millions USD